Osteoporosis: Epidemiology Forecast to 2027

  • ID: 4532604
  • Report
  • 41 pages
  • GlobalData
1 of 3
Osteoporosis: Epidemiology Forecast to 2027

Summary

Osteoporosis is a disease in which the density and quality of bone are reduced over time. In a normal process known as remodeling, some of a person’s bone cells dissolve (resorption) and new bone cells grow back (formation). The bones become so weak and brittle that a fall or even mild stresses such as bending over or coughing can cause a fracture.

To forecast the total prevalent cases and diagnosed prevalent cases of osteoporosis and osteopenia in the 7MM, epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. Epidemiologists obtained data for the total prevalent cases of osteoporosis secondary to glucocorticoid use from primary market research. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

In the 7MM, the total prevalent cases of osteoporosis will increase from 45,617,583 cases in 2017 to 52,482,628 cases in 2027, at an Annual Growth Rate (AGR) of 1.50%. In the 7MM, the diagnosed prevalent cases of osteoporosis will increase from 21,637,066 cases in 2017 to 24,553,120 cases in 2027, at an AGR of 1.35%. The author forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of osteoporosis during the forecast period.

Scope
  • The Osteoporosis Epidemiology Report provides an overview of the risk factors and global trends of osteoporosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of osteoporosis, and total and diagnosed prevalent cases of primary osteoporosis, segmented by sex and age in these markets. In addition, this report provides a 10-year epidemiological forecast for the total and diagnosed prevalent cases of secondary osteoporosis, total and diagnosed prevalent cases of osteopenia, segmented by sex. The report also includes the total and diagnosed prevalent cases of type 1 (postmenopausal) osteoporosis, and the total and diagnosed prevalent cases of type 2 (age-associated/ senile) osteoporosis, and total and diagnosed prevalent cases of osteoporosis secondary to glucocorticoid use.
  • The osteoporosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Osteoporosis Epidemiology report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global osteoporosis market.
  • Quantify patient populations in the global osteoporosis market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for osteoporosis therapeutics in each of the markets covered.
  • Understand magnitude of osteoporosis types in each market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Osteoporosis: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.5 Epidemiological Forecast for Osteoporosis (2017-2027)
3.5.1 Total Prevalent Cases of Osteoporosis
3.5.2 Age-Specific Total Prevalent Cases of Osteoporosis
3.5.3 Sex-Specific Total Prevalent Cases of Osteoporosis
3.5.4 Total Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis
3.5.5 Total Prevalent Cases of Primary Osteoporosis by Type
3.5.6 Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use
3.5.7 Diagnosed Prevalent Cases of Osteoporosis
3.5.8 Age-Specific Diagnosed Prevalent Cases of Osteoporosis
3.5.9 Sex-Specific Diagnosed Prevalent Cases of Osteoporosis
3.5.10 Diagnosed Prevalent Cases of Osteoporosis by Primary and Secondary Osteoporosis
3.5.11 Diagnosed Prevalent Cases of Primary Osteoporosis by Type
3.5.12 Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use
3.5.13 Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 High-Prescribing Physician Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About
4.5 Contact
4.6 Disclaimer

List of Tables
Table 1: Risk Factors and Comorbidities for Osteoporosis
Table 2: 7MM Total Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Table 3: 7MM, Total Prevalent Cases of Primary Osteoporosis by Type, Ages =30 Years, N, 2017
Table 4: 7MM Diagnosed Prevalent Cases of Osteoporosis by Primary Osteoporosis and Secondary Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Table 5: 7MM, Diagnosed Prevalent Cases of Primary Osteoporosis by Type, Ages =30 Years, N, 2017
Table 6: 7MM Total Prevalent Cases and Diagnosed Prevalent Cases of Osteopenia, Both Sexes, Ages =30 Years, N, 2017
Table 7: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017

List of Figures
Figure 1: 7MM, Total Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, 2017 and 2027
Figure 2: 7MM, Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, 2017 and 2027
Figure 3: 7MM, Age-Standardized Total Prevalence of Osteoporosis, Men and Women, Ages =30 Years, 2017
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Osteoporosis, Men and Women, Ages =30 Years, 2017
Figure 5: 7MM, Sources Used and Not Used to Forecast Total Prevalent Cases of Osteoporosis
Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases and Diagnosed Prevalent Cases of Primary and Secondary
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of Osteopenia
Figure 8: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteoporosis
Figure 9: 7MM, Sources Used to Forecast Diagnosed Prevalent Cases of Osteopenia
Figure 10: 7MM, Total Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 11: 7MM, Age-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 13: 7MM, Total Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages =30 Years, N, 2017
Figure 14: 7MM, Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Osteoporosis, Both Sexes, Ages =30 Years, N, 2017
Figure 17: 7MM, Diagnosed Prevalent Cases of Osteoporosis Secondary to Glucocorticoid Use, Both Sexes, Ages =30 Years, N, 2017
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll